BibTex RIS Kaynak Göster

Plasma Levels of Asymmetric Dimethylarginine and Total Homocysteine in First Degree Relatives of Type 2 Diabetic Patients

Yıl 2007, Cilt: 2007 Sayı: 1, 17 - 22, 01.01.2007

Sibel Güldiken Sibel Güldiken Hakan Karadağ Hakan Karadağ Muzaffer Demir Ender Arıkan Ender Arıkan Müjdat Kara

Öz

Objectives: Cardiovascular diseases are more common among first degree relatives of type 2 diabetic patients than healthy subjects without a family history of diabetes. Plasma asymmetric dimethylarginine (ADMA) and homocysteine (Hcy) levels are markers of endothelial dysfunction and cardiovascular disease. The objective of this study was to evaluate levels of ADMA, Hcy and their association with cardiovascular risk factors in first degree relatives of type 2 diabetic patients. Patients and Methods: The circulating ADMA and Hcy levels were measured in 15 first degree relatives of type 2 diabetic patients and 15 control subjects without a known family history of diabetes. Results: No statistically significant differences were found in plasma levels of ADMA and Hcy between the two groups (p>0.05). Plasma ADMA levels correlated significantly with waist circumference (p=0.02), fasting insulin levels (p=0.03), insulin resistance (p=0.01), total cholesterol (p=0.04) and HDL-cholesterol (p=0.03) levels in the first degree relatives of type 2 diabetic patients. Conclusion: These results suggest that plasma ADMA levels do not directly contribute to the development of endothelial dysfunction in first degree relatives of type 2 diabetic patients with cardiovascular risk factors. Turkish Başlık: Tip 2 Diyabetik Hastaların Birinci Derece Yakınlarında Total Homosistein ve Asimetrik Dimetilargininin Plazma Düzeyleri Anahtar Kelimeler: Tip 2 diabetes mellitus/genetik; N,N-dimetilarginin; homosistein Amaç: Tip 2 diyabetik hastaların birinci derece yakınlarında, ailesinde diyabet öyküsü olmayan sağlıklı olgulara göre kardiyovasküler hastalıklar daha sık görülmektedir. Asimetrik dimetilarginin (ADMA) ve homosistein (Hcy) plazma düzeyleri kardiyovasküler hastalıklar ve endotel disfonksiyonuyla ilişkili göstergelerdir. Bu çalışmada, tip 2 diyabetik hastaların birinci derece yakınlarında ADMA ve Hcy plazma düzeyleri ile bu göstergelerle kardiyovasküler risk faktörleri arasındaki ilişkilerin incelenmesi amaçlandı. Hastalar ve Yöntemler: Dolaşımdaki ADMA ve Hcy düzeyleri 15 tip 2 diyabet hastasının birinci derece yakınında ve ailesinde diyabet öyküsü olmayan 15 kontrol olgusunda ölçüldü. Bulgular: Her iki grup arasında ADMA ve Hcy plazma düzeyleri açısından anlamlı farklılık saptanmadı (p>0.05). Asimetrik dimetilarginin plazma düzeyi tip 2 diyabetik olguların birinci derece yakınlarında, bel çevresi (p=0.02), açlık insülin düzeyi (p=0.03), insülin direnci (p=0.01), total kolesterol (p=0.04) ve HDL kolesterol (p=0.03) ile ilişkiliydi. Sonuç: Bu sonuçlara göre, kardiyovasküler risk faktörlerine sahip olan tip 2 diyabetik olguların birinci derece yakınlarında, ADMA plazma düzeylerinin doğrudan endotel disfonksiyonunun gelişimine katkıda bulunmadığını düşünmekteyiz.

Anahtar Kelimeler

Diabetes mellitus type 2/genetics; N N-dimethylarginine; homocysteine

Kaynakça

  • Pannacciulli N, De Pergola G, Ciccone M, Rizzon P, Giorgino F, Giorgino R. Effect of family history of type 2 diabetes on the intima-media thickness of the common carotid artery in normal-weight, over- weight, and obese glucose-tolerant young adults. Diabetes Care 2003;26:1230-4.
  • Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003;8:71-86.
  • Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 Suppl 12:S60-2.
  • Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asym- metric dimethylarginine. Circulation 2003;108:933-8.
  • Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes melli- tus. Diabetes Care 2003;26 Suppl 1:S5-20.
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assess- ment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
  • Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethy- larginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal (ADMA): a novel risk factor for endothelial dysfunc- tion: its role in hypercholesterolemia. Circulation 1998;98:1842-7.
  • Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentra- tions of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-3.
  • Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-6.
  • Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51:843-6.
  • Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethy- laminohydrolase. Circulation 2002;106:987-92.
  • Herlihy OM, Barrow BA, Grant PJ, Levy JC. Hyperglycaemic siblings of Type II (non-insulin- dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. Diabetologia 2002;45:635-41.
  • Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
  • JR, Tangphao O, et al. Asymmetric dimethylarginine

Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein ve Asimetrik Dimetilargininin Plazma Düzeyleri

Yıl 2007, Cilt: 2007 Sayı: 1, 17 - 22, 01.01.2007

Sibel Güldiken Sibel Güldiken Hakan Karadağ Hakan Karadağ Muzaffer Demir Ender Arıkan Ender Arıkan Müjdat Kara

Öz

Anahtar Kelimeler

Tip 2 diabetes mellitus/genetik N N-dimetilarginin homosistein.

Kaynakça

  • Pannacciulli N, De Pergola G, Ciccone M, Rizzon P, Giorgino F, Giorgino R. Effect of family history of type 2 diabetes on the intima-media thickness of the common carotid artery in normal-weight, over- weight, and obese glucose-tolerant young adults. Diabetes Care 2003;26:1230-4.
  • Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003;8:71-86.
  • Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 Suppl 12:S60-2.
  • Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asym- metric dimethylarginine. Circulation 2003;108:933-8.
  • Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes melli- tus. Diabetes Care 2003;26 Suppl 1:S5-20.
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assess- ment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
  • Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethy- larginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal (ADMA): a novel risk factor for endothelial dysfunc- tion: its role in hypercholesterolemia. Circulation 1998;98:1842-7.
  • Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentra- tions of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-3.
  • Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-6.
  • Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51:843-6.
  • Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethy- laminohydrolase. Circulation 2002;106:987-92.
  • Herlihy OM, Barrow BA, Grant PJ, Levy JC. Hyperglycaemic siblings of Type II (non-insulin- dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. Diabetologia 2002;45:635-41.
  • Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
  • JR, Tangphao O, et al. Asymmetric dimethylarginine
Toplam 14 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Sibel Güldiken Bu kişi benim

Sibel Güldiken Bu kişi benim

Hakan Karadağ Bu kişi benim

Hakan Karadağ Bu kişi benim

Muzaffer Demir Bu kişi benim

Ender Arıkan Bu kişi benim

Ender Arıkan Bu kişi benim

Müjdat Kara Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2007
Yayımlandığı Sayı Yıl 2007 Cilt: 2007 Sayı: 1

Kaynak Göster

APA Güldiken, S., Güldiken, S., Karadağ, H., Karadağ, H., vd. (2007). Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein ve Asimetrik Dimetilargininin Plazma Düzeyleri. Balkan Medical Journal, 2007(1), 17-22.
AMA Güldiken S, Güldiken S, Karadağ H, Karadağ H, Demir M, Arıkan E, Arıkan E, Kara M. Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein ve Asimetrik Dimetilargininin Plazma Düzeyleri. Balkan Medical Journal. Ocak 2007;2007(1):17-22.
Chicago Güldiken, Sibel, Sibel Güldiken, Hakan Karadağ, Hakan Karadağ, Muzaffer Demir, Ender Arıkan, Ender Arıkan, ve Müjdat Kara. “Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein Ve Asimetrik Dimetilargininin Plazma Düzeyleri”. Balkan Medical Journal 2007, sy. 1 (Ocak 2007): 17-22.
EndNote Güldiken S, Güldiken S, Karadağ H, Karadağ H, Demir M, Arıkan E, Arıkan E, Kara M (01 Ocak 2007) Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein ve Asimetrik Dimetilargininin Plazma Düzeyleri. Balkan Medical Journal 2007 1 17–22.
IEEE S. Güldiken, “Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein ve Asimetrik Dimetilargininin Plazma Düzeyleri”, Balkan Medical Journal, c. 2007, sy. 1, ss. 17–22, 2007.
ISNAD Güldiken, Sibel vd. “Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein Ve Asimetrik Dimetilargininin Plazma Düzeyleri”. Balkan Medical Journal 2007/1 (Ocak 2007), 17-22.
JAMA Güldiken S, Güldiken S, Karadağ H, Karadağ H, Demir M, Arıkan E, Arıkan E, Kara M. Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein ve Asimetrik Dimetilargininin Plazma Düzeyleri. Balkan Medical Journal. 2007;2007:17–22.
MLA Güldiken, Sibel vd. “Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein Ve Asimetrik Dimetilargininin Plazma Düzeyleri”. Balkan Medical Journal, c. 2007, sy. 1, 2007, ss. 17-22.
Vancouver Güldiken S, Güldiken S, Karadağ H, Karadağ H, Demir M, Arıkan E, Arıkan E, Kara M. Tip 2 Diyabetik Hastaların Birinci Derece Yak›nlarında Total Homosistein ve Asimetrik Dimetilargininin Plazma Düzeyleri. Balkan Medical Journal. 2007;2007(1):17-22.